dc.contributor
Institut Català de la Salut
dc.contributor
[González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Soler Romeo, Maria Jose
dc.contributor.author
Facila, Lorenzo
dc.contributor.author
Gorriz, Jose Luis
dc.contributor.author
Ortiz Arduan, Alberto
dc.contributor.author
González Juanatey, José Ramón
dc.contributor.author
Valle, Alfonso
dc.date.accessioned
2025-10-24T10:19:30Z
dc.date.available
2025-10-24T10:19:30Z
dc.date.issued
2023-03-03T13:33:11Z
dc.date.issued
2023-03-03T13:33:11Z
dc.date.issued
2023-01-31
dc.identifier
González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023 Jan 31;55(1):502–13.
dc.identifier
https://hdl.handle.net/11351/9108
dc.identifier
10.1080/07853890.2023.2171110
dc.identifier
000919979500001
dc.identifier.uri
https://hdl.handle.net/11351/9108
dc.description.abstract
Albuminuria; Enfermedad renal crónica; Finerenona
dc.description.abstract
Albuminúria; Malaltia renal crònica; Finerenona
dc.description.abstract
Albuminuria; Chronic kidney disease; Finerenone
dc.description.abstract
Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.
dc.format
application/pdf
dc.publisher
Taylor & Francis
dc.relation
Annals of Medicine;55(1)
dc.relation
https://doi.org/10.1080/07853890.2023.2171110
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Diabetis no-insulinodependent - Complicacions
dc.subject
Insuficiència renal crònica - Complicacions
dc.subject
Sistema cardiovascular - Malalties - Diagnòstic
dc.subject
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
dc.subject
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic
dc.subject
DISEASES::Cardiovascular Diseases
dc.subject
CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Mineralocorticoid Receptor Antagonists
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II
dc.subject
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica
dc.subject
ENFERMEDADES::enfermedades cardiovasculares
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de receptores de mineralocorticoides
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Cardiorenal benefits of finerenone: protecting kidney and heart
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
